Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Biochemical premotor biomarkers for Parkinson's disease.

Literature DB >> 22508282

Biochemical premotor biomarkers for Parkinson's disease.

Abstract

A biomarker is a biological characteristic that is objectively measured and evaluated as an indicator of normal biological or pathologic processes or of pharmacologic responses to a therapeutic intervention. We reviewed the current status of target protein biomarkers (eg, total/oligomeric α-synuclein and DJ-1) in cerebrospinal fluid, as well as on unbiased processes that can be used to discover novel biomarkers. We have also provide details about strategies toward potential populations/models and technologies, including the need for standardized sampling techniques, to pursue the identification of new biochemical markers in the premotor stage of Parkinson's disease in the future.

Entities: Chemical Disease Gene Mutation Species

Mesh：

Substances：

Year: 2012 PMID： 22508282 PMCID： PMC3428741 DOI： 10.1002/mds.24956

Source DB: PubMed Journal: Mov Disord ISSN： 0885-3185 Impact factor: 10.338

60 in total

1. Metabotropic glutamate receptor 5 antagonist protects dopaminergic and noradrenergic neurons from degeneration in MPTP-treated monkeys.

Authors: Gunasingh J Masilamoni; James W Bogenpohl; David Alagille; Kristen Delevich; Gilles Tamagnan; John R Votaw; Thomas Wichmann; Yoland Smith
Journal: Brain Date: 2011-07 Impact factor: 13.501

2. Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease.

Authors: Takahiko Tokuda; Sultan A Salem; David Allsop; Toshiki Mizuno; Masanori Nakagawa; Mohamed M Qureshi; Joseph J Locascio; Michael G Schlossmacher; Omar M A El-Agnaf
Journal: Biochem Biophys Res Commun Date: 2006-08-14 Impact factor: 3.575

3. Flow rate of cerebrospinal fluid (CSF)--a concept common to normal blood-CSF barrier function and to dysfunction in neurological diseases.

Authors: H Reiber
Journal: J Neurol Sci Date: 1994-04 Impact factor: 3.181

4. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.

Authors: A J Hughes; S E Daniel; L Kilford; A J Lees
Journal: J Neurol Neurosurg Psychiatry Date: 1992-03 Impact factor: 10.154

5. Lewy pathology in the submandibular gland of individuals with incidental Lewy body disease and sporadic Parkinson's disease.

Authors: Kelly Del Tredici; Christopher H Hawkes; Estifanos Ghebremedhin; Heiko Braak
Journal: Acta Neuropathol Date: 2010-03-14 Impact factor: 17.088

6. Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology.

Authors: Annika Olsson; Hugo Vanderstichele; Niels Andreasen; Geert De Meyer; Anders Wallin; Björn Holmberg; Lars Rosengren; Eugeen Vanmechelen; Kaj Blennow
Journal: Clin Chem Date: 2004-11-24 Impact factor: 8.327

7. Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease.

Authors: John P Anderson; Donald E Walker; Jason M Goldstein; Rian de Laat; Kelly Banducci; Russell J Caccavello; Robin Barbour; Jiping Huang; Kristin Kling; Michael Lee; Linnea Diep; Pamela S Keim; Xiaofeng Shen; Tim Chataway; Michael G Schlossmacher; Peter Seubert; Dale Schenk; Sukanto Sinha; Wei Ping Gai; Tamie J Chilcote
Journal: J Biol Chem Date: 2006-07-17 Impact factor: 5.157

8. Alpha-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma.

Authors: Omar M A El-Agnaf; Sultan A Salem; Katerina E Paleologou; Leanne J Cooper; Nigel J Fullwood; Mark J Gibson; Martin D Curran; Jennifer A Court; David M A Mann; Shu-ichi Ikeda; Mark R Cookson; John Hardy; David Allsop
Journal: FASEB J Date: 2003-08-15 Impact factor: 5.191

9. CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases.

Authors: Jing Zhang; Izabela Sokal; Elaine R Peskind; Joseph F Quinn; Joseph Jankovic; Christopher Kenney; Kathryn A Chung; Steven P Millard; John G Nutt; Thomas J Montine
Journal: Am J Clin Pathol Date: 2008-04 Impact factor: 2.493

Review 10. Linking DJ-1 to neurodegeneration offers novel insights for understanding the pathogenesis of Parkinson's disease.

Authors: Vincenzo Bonifati; Ben A Oostra; Peter Heutink
Journal: J Mol Med (Berl) Date: 2004-01-08 Impact factor: 4.599

9 in total

Biochemical premotor biomarkers for Parkinson's disease.

1. Metabotropic glutamate receptor 5 antagonist protects dopaminergic and noradrenergic neurons from degeneration in MPTP-treated monkeys.

2. Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease.

3. Flow rate of cerebrospinal fluid (CSF)--a concept common to normal blood-CSF barrier function and to dysfunction in neurological diseases.

4. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.

5. Lewy pathology in the submandibular gland of individuals with incidental Lewy body disease and sporadic Parkinson's disease.

6. Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology.

7. Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease.

8. Alpha-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma.

9. CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases.

Review 10. Linking DJ-1 to neurodegeneration offers novel insights for understanding the pathogenesis of Parkinson's disease.

1. What about biomarkers for parkinson's disease?

Review 2. Cerebrospinal fluid biomarkers in Parkinson disease.

Review 3. Is there a need to redefine Parkinson's disease?

4. Synuclein-One study: skin biopsy detection of phosphorylated α-synuclein for diagnosis of synucleinopathies.

Review 5. Recent developments in biomarkers in Parkinson disease.

Review 6. The Concept of Prodromal Parkinson's Disease.

7. Cerebrospinal fluid biomarker candidates for parkinsonian disorders.

Review 8. Development of early diagnosis of Parkinson's disease: Illusion or reality?

Review 9. Modulation of the Interactions Between α-Synuclein and Lipid Membranes by Post-translational Modifications.